ASND · Categories · M&A
ASND - Mergers and acquisitions
Ascendis Pharma A/S (ASND) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for ASND
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementNEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Ascendis Pharma A/S (NASDAQ:ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath. "We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, as we launch Yorvipath in the U.S. as the first and only FDA approved treatment of hypoparathyroidism in adults," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "This transa
- Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementCOPENHAGEN, Denmark and NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) and Royalty Pharma plc (NASDAQ:RPRX) today announced that Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of YORVIPATH. "We are pleased to again partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, as we launch YORVIPATH in the U.S. as the first and only FDA approved treatment of hypoparathyroidism in adults," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "This trans
- Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement• Proceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Ascendis Pharma A/S (NASDAQ:ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa revenue. "This transaction reflects the significant value of Skytrofa. We are pleased to partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, and look forward to partnering with them in the coming years," said Jan Mikkelsen, Ascendis
- Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement- Proceeds to support continued development and commercialization of Endocrine Rare Disease products, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) and Royalty Pharma plc (NASDAQ:RPRX) today announced that Ascendis has entered into a $150 million capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue. "This transaction reflects the significant value of SKYTROFA. We are pleased to partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, and look forward to partnering with them in the coming years," said Jan Mikkelsen, Ascendis